Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 6/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | GSK3B | P49841 | 6/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728667 | 0.93 | RIOK2 (0.49) | RIOK2TYK2ALDH1A1MAPTGSK3B | |
| SCHEMBL19736190 | 0.85 | ALDH1A1 (0.46) | RIOK2TYK2ALDH1A1GCK | |
| SCHEMBL24598427 | 0.85 | NPC1 (0.51) | RIOK2TYK2ALDH1A1MAPTGSK3B | |
| SCHEMBL19728668 | 0.84 | RIOK2 (0.46) | RIOK2TYK2ALDH1A1MAPTGSK3B | |
| SCHEMBL19728675 | 0.82 | RIOK2 (0.49) | RIOK2TYK2ALDH1A1MAPTGSK3B | |
| SCHEMBL19699541 | 0.82 | RIOK2 (0.46) | RIOK2TYK2MAPTGSK3BGCK | |
| SCHEMBL19699543 | 0.82 | RIOK2 (0.46) | RIOK2TYK2MAPTGSK3BGCK | |
| SCHEMBL19728660 | 0.81 | RIOK2 (0.67) | RIOK2TYK2ALDH1A1MAPTGSK3A | |
| SCHEMBL26550286 | 0.80 | HTR7 (0.40) | RIOK2ALDH1A1MAPK10 | |
| SCHEMBL19699470 | 0.79 | RIOK2 (0.46) | RIOK2TYK2ALDH1A1MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RIOK2 2619/4885TYK2 2258/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.